NEW YORK (GenomeWeb News) — Asuragen Pharmacogenomic Services today said it has licensed real-time quantitative PCR technology from Roche Molecular Systems that will enable it to perform clinical gene-expression profiling and DNA analysis.
 
Asuragen said the IP, together with its microRNA and mRNA profiling services, can be used to test predictive biomarker signatures, efficacy markers, and assess patient stratification during clinical drug trials.
 
Financial terms of the agreement were not released.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.